Indo Us Biotech Limited has informed the Exchange about Confirmation regarding not falling under the Large Corporate Criteria with reference to SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018
INDOUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Indo Us Biotech Limited has submitted a compliance filing to the stock exchanges confirming that it does not meet the criteria to be classified as a 'Large Corporate' under SEBI's 2018 framework. This means the company is not subject to the mandatory requirement of raising at least 25% of its incremental borrowings through debt securities. The confirmation was submitted by the Company Secretary, Dimpy Joshi, on April 30, 2026, in line with the annual disclosure obligation under the SEBI circular. No financial numbers or capital raising details are mentioned in this filing.
This is a routine annual regulatory compliance disclosure and is unlikely to have any meaningful impact on the stock price or shareholder value. It simply confirms the company's smaller size relative to SEBI's large corporate thresholds.